Minimum Deposit Casinos Warns of Sweeping Changes as States Crack Down on Online Sweepstakes Casinos

WATERFORD, Ireland, May 12, 2025 (GLOBE NEWSWIRE) — Minimum Deposit Casinos (MDC), a leading global online casino review hub and division of the OneTwenty Group, has released new insights into the tightening regulatory landscape for sweepstakes-based gaming in the United States. Recent moves by lawmakers in New York, Louisiana, and Montana suggest a coordinated push to eliminate or restrict these alternative online gambling models.

In New York, Senate Bill 5935, introduced by Sen. Joseph Addabbo, has advanced through the legislative process and targets the operation and supply of sweepstakes-style platforms. The bill specifically addresses platforms that use two forms of digital currency — one of which can be redeemed for real-world prizes — a setup now under scrutiny by state regulators.

Meanwhile, Louisiana has taken a similarly hard stance with Senate Bill 181, led by Sen. Adam Bass. The bill aims to ban all forms of sweepstakes games that mimic casino or sports betting experiences, including both the promotion and operation of such services. It passed the state Senate unanimously and is currently being reviewed by the House.

Montana could become the first U.S. state to enact a full prohibition if Senate Bill 555 is signed into law. The bill, which has passed both chambers, seeks to clearly define and outlaw the operation of unlicensed sweepstakes gambling websites.

“States are clearly starting to zero in on grey-area gambling models,” said a senior analyst at MDC. “These bills show how quickly the legal landscape can shift, and it’s crucial that players and operators stay ahead of the curve.”

About MDC
Minimum Deposit Casinos (MDC) is a trusted online portal under the OneTwenty Group. MDC evaluates online casinos worldwide, assessing safety, licensing, game fairness, and payment security before recommending the best options to players.

Contact Email: [email protected]

GlobeNewswire Distribution ID 1001095989

CGTN:How do stable China-Russia ties contribute to a turbulent world?

BEIJING, May 08, 2025 (GLOBE NEWSWIRE) — A natural gas pipeline that stretches 3,000 kilometers in Russia and 5,111 km in China commenced operations in December last year, benefiting about 450 million people along its route.

The China-Russia east-route natural gas pipeline is a landmark project of energy cooperation between the two countries, yet ties between the two neighboring nations go far beyond that.

In 2024, bilateral trade rose to $244.8 billion, making China the largest trading partner of Russia for 15 consecutive years. At the leadership level, the two heads of state have met more than 40 times on various occasions over the years.

In the face of unprecedented global changes, China and Russia have continuously deepened political mutual trust and strategic coordination, maintained close cooperation in international affairs, and injected valuable stability and positive energy into a turbulent world, visiting Chinese President Xi Jinping told his Russian counterpart Vladimir Putin in Moscow on Thursday.

Xi arrived in Russia on Wednesday for a state visit and to attend celebrations marking the 80th anniversary of the victory in Soviet Union’s Great Patriotic War.

A pillar of stability

Xi urged China and Russia to resolutely defend the rights and interests of the two countries and the vast number of developing countries in the face of the countercurrent of unilateralism and the acts of power politics and bullying in the world.

He called for an equal and orderly multipolar world and a universally beneficial and inclusive economic globalization, noting that this is also an inevitable choice for both sides to achieve mutual success and promote their own development and revitalization.

China will work with Russia to shoulder the special responsibility as major countries of the world and permanent members of the UN Security Council, Xi added.

Feng Shaolei, director of the Center for Russian Studies at East China Normal University in Shanghai, pointed out that President Xi’s visit – like his previous trips to Russia – aims to strengthen the long-standing friendship and strategic partnership between the two countries, and help maintain peace and stability in both the region and the wider world.

Feng emphasized that both countries advocate an independent and autonomous approach to managing their internal and external affairs, and he believes the China-Russia relationship serves as a stabilizing anchor amid global transformation.

Wang Yong, a professor at Peking University’s School of International Studies, said the world is at a critical moment, and China and Russia should step up cooperation under multilateral platforms to guide global governance in the right direction and push back against unilateralism and bullying.

For China and Russia, joining hands to build a community with a shared future for mankind and contributing more stability and positive energy to the international community is far wiser and more meaningful than engaging in geopolitics, Wang added.

Resilient ties

Hailing long-term good-neighborly friendship and mutually beneficial cooperation as distinct features of bilateral ties, President Xi remarked that China-Russia relations have become more confident, stable and resilient in the new era. Putin echoed the sentiment, saying the relationship is built on mutual respect and equality and is not swayed by external circumstances.

The two presidents on Thursday witnessed the signing and exchange of over 20 bilateral cooperation documents, covering areas such as global strategic stability, upholding the authority of international law, investment protection, digital economy, quarantine and film cooperation.

Professor Feng emphasized that pragmatic cooperation remains the strongest internal driver of the China-Russia partnership. While traditional areas such as energy, aerospace and infrastructure remain key pillars, the two countries are expanding cooperation into emerging sectors including the digital economy, biomedicine and green development.

Cultural and people-to-people exchanges have also gained momentum. In 2023, the two leaders agreed to make 2024 and 2025 the China-Russia Years of Culture, launching hundreds of exchange activities such as exhibitions, film screenings and academic collaborations.

On top of that, the two sides have made impressive strides in educational cooperation. More than 200 Russian universities now offer Chinese language courses, with some 90,000 students studying the language. Meanwhile, over 40,000 Chinese students are pursuing studies in Russia.

https://news.cgtn.com/news/2025-05-09/How-do-stable-China-Russia-ties-contribute-to-a-turbulent-world–1DdAJds4GT6/p.html

Contact: CGTN, [email protected]

GlobeNewswire Distribution ID 9448157

CGTN:How do stable China-Russia ties contribute to a turbulent world?

BEIJING, May 08, 2025 (GLOBE NEWSWIRE) — A natural gas pipeline that stretches 3,000 kilometers in Russia and 5,111 km in China commenced operations in December last year, benefiting about 450 million people along its route.

The China-Russia east-route natural gas pipeline is a landmark project of energy cooperation between the two countries, yet ties between the two neighboring nations go far beyond that.

In 2024, bilateral trade rose to $244.8 billion, making China the largest trading partner of Russia for 15 consecutive years. At the leadership level, the two heads of state have met more than 40 times on various occasions over the years.

In the face of unprecedented global changes, China and Russia have continuously deepened political mutual trust and strategic coordination, maintained close cooperation in international affairs, and injected valuable stability and positive energy into a turbulent world, visiting Chinese President Xi Jinping told his Russian counterpart Vladimir Putin in Moscow on Thursday.

Xi arrived in Russia on Wednesday for a state visit and to attend celebrations marking the 80th anniversary of the victory in Soviet Union’s Great Patriotic War.

A pillar of stability

Xi urged China and Russia to resolutely defend the rights and interests of the two countries and the vast number of developing countries in the face of the countercurrent of unilateralism and the acts of power politics and bullying in the world.

He called for an equal and orderly multipolar world and a universally beneficial and inclusive economic globalization, noting that this is also an inevitable choice for both sides to achieve mutual success and promote their own development and revitalization.

China will work with Russia to shoulder the special responsibility as major countries of the world and permanent members of the UN Security Council, Xi added.

Feng Shaolei, director of the Center for Russian Studies at East China Normal University in Shanghai, pointed out that President Xi’s visit – like his previous trips to Russia – aims to strengthen the long-standing friendship and strategic partnership between the two countries, and help maintain peace and stability in both the region and the wider world.

Feng emphasized that both countries advocate an independent and autonomous approach to managing their internal and external affairs, and he believes the China-Russia relationship serves as a stabilizing anchor amid global transformation.

Wang Yong, a professor at Peking University’s School of International Studies, said the world is at a critical moment, and China and Russia should step up cooperation under multilateral platforms to guide global governance in the right direction and push back against unilateralism and bullying.

For China and Russia, joining hands to build a community with a shared future for mankind and contributing more stability and positive energy to the international community is far wiser and more meaningful than engaging in geopolitics, Wang added.

Resilient ties

Hailing long-term good-neighborly friendship and mutually beneficial cooperation as distinct features of bilateral ties, President Xi remarked that China-Russia relations have become more confident, stable and resilient in the new era. Putin echoed the sentiment, saying the relationship is built on mutual respect and equality and is not swayed by external circumstances.

The two presidents on Thursday witnessed the signing and exchange of over 20 bilateral cooperation documents, covering areas such as global strategic stability, upholding the authority of international law, investment protection, digital economy, quarantine and film cooperation.

Professor Feng emphasized that pragmatic cooperation remains the strongest internal driver of the China-Russia partnership. While traditional areas such as energy, aerospace and infrastructure remain key pillars, the two countries are expanding cooperation into emerging sectors including the digital economy, biomedicine and green development.

Cultural and people-to-people exchanges have also gained momentum. In 2023, the two leaders agreed to make 2024 and 2025 the China-Russia Years of Culture, launching hundreds of exchange activities such as exhibitions, film screenings and academic collaborations.

On top of that, the two sides have made impressive strides in educational cooperation. More than 200 Russian universities now offer Chinese language courses, with some 90,000 students studying the language. Meanwhile, over 40,000 Chinese students are pursuing studies in Russia.

https://news.cgtn.com/news/2025-05-09/How-do-stable-China-Russia-ties-contribute-to-a-turbulent-world–1DdAJds4GT6/p.html

Contact: CGTN, [email protected]

GlobeNewswire Distribution ID 9448157

EAACI Hong Kong Allergy School 2025: A Landmark in Global Allergy Education

ZURICH, May 08, 2025 (GLOBE NEWSWIRE) — The European Academy of Allergy & Clinical Immunology (EAACI), in partnership with the Hong Kong Institute of Allergy (HKIA), is proud to announce the inaugural EAACI Hong Kong Allergy School. This significant milestone will unfold in Hong Kong – Asia’s World City – a dynamic hub where East meets West, innovation meets tradition, and global minds converge.

Under the theme “East Meets West”, the 2025 edition of the Allergy School represents a bold step in fostering cross-continental collaboration in allergy and clinical immunology. By bringing together leading global experts, this flagship event aims to enrich knowledge exchange, advance clinical practices, and inspire innovative solutions to allergy care worldwide.

Participants will benefit from a rich, interdisciplinary scientific programme, featuring renowned international faculty and cutting-edge topics across the allergy and immunology spectrum. A special dedicated Chinese-language track will be available, promoting inclusivity and greater accessibility for Chinese-speaking professionals.

Attendees will also present their research through oral and poster sessions, connect with industry leaders, and build lasting collaborations within the global allergy community. Prizes will be awarded to top abstracts as selected by EAACI’s international panel of experts.

In celebration of this milestone, EAACI is offering exclusive benefits:

  • Discounted registration for current EAACI members
  • A complimentary 1-year EAACI membership for registered delegates that are not EAACI members

We invite you to submit your abstracts and take advantage of early bird registration, available now. The abstract submission deadline is 31st May 2025.

As we gather to celebrate innovation, partnership, and progress, we also invite you to experience the vibrant city of Hong Kong – its iconic skyline, diverse cuisine, and cultural richness – the perfect setting for this global exchange.

Join us in shaping the future of allergy science and care. Your participation will help build a thriving; interconnected network of professionals dedicated to better outcomes for patients everywhere.

Explore the programme, register, and plan your visit at:
https://eaaci.org/other_events/eaaci-hong-kong-allergy-school-2025/

About EAACI

The European Academy of Allergy and Clinical Immunology (EAACI) is the leading professional organization dedicated to excellence in allergy and immunology. Learn more at https://eaaci.org.

Contact: [email protected]

+41 44 205 55 33

GlobeNewswire Distribution ID 1001095348

EAACI Hong Kong Allergy School 2025: A Landmark in Global Allergy Education

ZURICH, May 08, 2025 (GLOBE NEWSWIRE) — The European Academy of Allergy & Clinical Immunology (EAACI), in partnership with the Hong Kong Institute of Allergy (HKIA), is proud to announce the inaugural EAACI Hong Kong Allergy School. This significant milestone will unfold in Hong Kong – Asia’s World City – a dynamic hub where East meets West, innovation meets tradition, and global minds converge.

Under the theme “East Meets West”, the 2025 edition of the Allergy School represents a bold step in fostering cross-continental collaboration in allergy and clinical immunology. By bringing together leading global experts, this flagship event aims to enrich knowledge exchange, advance clinical practices, and inspire innovative solutions to allergy care worldwide.

Participants will benefit from a rich, interdisciplinary scientific programme, featuring renowned international faculty and cutting-edge topics across the allergy and immunology spectrum. A special dedicated Chinese-language track will be available, promoting inclusivity and greater accessibility for Chinese-speaking professionals.

Attendees will also present their research through oral and poster sessions, connect with industry leaders, and build lasting collaborations within the global allergy community. Prizes will be awarded to top abstracts as selected by EAACI’s international panel of experts.

In celebration of this milestone, EAACI is offering exclusive benefits:

  • Discounted registration for current EAACI members
  • A complimentary 1-year EAACI membership for registered delegates that are not EAACI members

We invite you to submit your abstracts and take advantage of early bird registration, available now. The abstract submission deadline is 31st May 2025.

As we gather to celebrate innovation, partnership, and progress, we also invite you to experience the vibrant city of Hong Kong – its iconic skyline, diverse cuisine, and cultural richness – the perfect setting for this global exchange.

Join us in shaping the future of allergy science and care. Your participation will help build a thriving; interconnected network of professionals dedicated to better outcomes for patients everywhere.

Explore the programme, register, and plan your visit at:
https://eaaci.org/other_events/eaaci-hong-kong-allergy-school-2025/

About EAACI

The European Academy of Allergy and Clinical Immunology (EAACI) is the leading professional organization dedicated to excellence in allergy and immunology. Learn more at https://eaaci.org.

Contact: [email protected]

+41 44 205 55 33

GlobeNewswire Distribution ID 1001095348

Zoom and ServiceNow Announce Strategic Integration to Elevate Customer and Employee Experiences

Unified Engagement from Zoom CX and ServiceNow integrates voice, video, and digital channels directly within the ServiceNow AI Platform for a simpler agent experience and more personalized customer engagements

LAS VEGAS, May 07, 2025 (GLOBE NEWSWIRE) — Zoom Communications Inc. (NASDAQ: ZM) and ServiceNow (NYSE: NOW), the AI platform for business transformation, today announced plans to integrate Zoom CX with ServiceNow CRM and IT Service Management (ITSM). The integration, announced as part of Knowledge 2025, ServiceNow’s annual customer and partner event, will deliver a turnkey, AI-first solution for customer service and IT support in the contact center.

“This integration unites the power of Zoom’s AI-first omnichannel contact center platform with ServiceNow’s CRM and Industry workflows, bringing voice, video, and digital interactions directly into the flow of work for service teams, making the experience more seamless and robust,” said Kentis Gopalla, head of product for Zoom CX. “This partnership underscores our commitment to providing solutions that drive business success and simplify customer and employee interactions.”

“Customer experiences should be easy, personalized, and fast — not stalled by disconnected systems or unhelpful bots,” said Michael Ramsey, GVP, Product Management, CRM and Industry Workflows at ServiceNow. “With ServiceNow CRM and Zoom CX coming together in one unified experience, we’re eliminating the need to swivel between tools and giving CX teams the context, data, and AI they need to resolve issues faster and create deeper customer connections.”

Key Benefits of the Zoom + ServiceNow Integration

  • A Unified Workspace That Puts Agents in Control
    With Zoom CX embedded inside the ServiceNow Agent Workspace, agents manage every interaction, whether voice, video, or chat, without leaving the platform. Instead of toggling between systems, they can stay focused on the customer, supported by real-time access to CRM data, interaction history, entitlements, and open cases.

    Combined with ServiceNow’s Industry workflows, agents can take action in context, triggering the right processes, resolving issues faster, and delivering a more tailored experience, whether it’s helping a patient reschedule an appointment, a banking client check on a loan application, or a retailer process a return.

  • Personalized, AI-First Experiences That Scale
    Combining Zoom’s AI capabilities with ServiceNow’s automation and CRM intelligence enables organizations to scale support without sacrificing personalization. Zoom Virtual Agent can handle customer issues with context-aware responses. Agents benefit from AI Expert Assist to provide real-time sentiment analysis, smart note-taking, and automatic call dispositioning, keeping them focused on high-value interactions instead of repetitive tasks.

    Additionally, Zoom’s AI-first quality management can automatically score every interaction and generate coaching opportunities to drive continuous optimization.

  • Accelerate Resolution Through Seamless Collaboration
    Support doesn’t always end with the first agent. Sometimes it takes a team, from billing to field service to engineering. With Zoom’s collaboration tools accessible within ServiceNow, agents can bring in the right expert without switching tools or losing context, helping them resolve issues faster and with the right team.

Availability

Unified Engagement from Zoom CX and ServiceNow will be available later this year through the ServiceNow Store.

About Zoom

Zoom’s mission is to provide an AI-first work platform for human connection. Reimagine teamwork with Zoom Workplace — Zoom’s open collaboration platform with AI Companion empowers teams to be more productive. Together with Zoom Workplace, Zoom’s Business Services for sales, marketing, and customer experience teams, including Zoom Contact Center, strengthen customer relationships throughout the customer lifecycle. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more information at zoom.com.

About ServiceNow 
ServiceNow (NYSE: NOW) is putting AI to work for people. We move with the pace of innovation to help customers transform organizations across every industry while upholding a trustworthy, human centered approach to deploying our products and services at scale. Our AI platform for business transformation connects people, processes, data, and devices to increase productivity and maximize business outcomes. For more information, visit: www.servicenow.com.

© 2025 ServiceNow, Inc. All rights reserved. ServiceNow, the ServiceNow logo, Now, and other ServiceNow marks are trademarks and/or registered trademarks of ServiceNow, Inc. in the United States and/or other countries. Other company names, product names, and logos may be trademarks of the respective companies with which they are associated.

Zoom Public Relations
Karen Modlin
[email protected]

GlobeNewswire Distribution ID 9445948

Zoom and ServiceNow Announce Strategic Integration to Elevate Customer and Employee Experiences

Unified Engagement from Zoom CX and ServiceNow integrates voice, video, and digital channels directly within the ServiceNow AI Platform for a simpler agent experience and more personalized customer engagements

LAS VEGAS, May 07, 2025 (GLOBE NEWSWIRE) — Zoom Communications Inc. (NASDAQ: ZM) and ServiceNow (NYSE: NOW), the AI platform for business transformation, today announced plans to integrate Zoom CX with ServiceNow CRM and IT Service Management (ITSM). The integration, announced as part of Knowledge 2025, ServiceNow’s annual customer and partner event, will deliver a turnkey, AI-first solution for customer service and IT support in the contact center.

“This integration unites the power of Zoom’s AI-first omnichannel contact center platform with ServiceNow’s CRM and Industry workflows, bringing voice, video, and digital interactions directly into the flow of work for service teams, making the experience more seamless and robust,” said Kentis Gopalla, head of product for Zoom CX. “This partnership underscores our commitment to providing solutions that drive business success and simplify customer and employee interactions.”

“Customer experiences should be easy, personalized, and fast — not stalled by disconnected systems or unhelpful bots,” said Michael Ramsey, GVP, Product Management, CRM and Industry Workflows at ServiceNow. “With ServiceNow CRM and Zoom CX coming together in one unified experience, we’re eliminating the need to swivel between tools and giving CX teams the context, data, and AI they need to resolve issues faster and create deeper customer connections.”

Key Benefits of the Zoom + ServiceNow Integration

  • A Unified Workspace That Puts Agents in Control
    With Zoom CX embedded inside the ServiceNow Agent Workspace, agents manage every interaction, whether voice, video, or chat, without leaving the platform. Instead of toggling between systems, they can stay focused on the customer, supported by real-time access to CRM data, interaction history, entitlements, and open cases.

    Combined with ServiceNow’s Industry workflows, agents can take action in context, triggering the right processes, resolving issues faster, and delivering a more tailored experience, whether it’s helping a patient reschedule an appointment, a banking client check on a loan application, or a retailer process a return.

  • Personalized, AI-First Experiences That Scale
    Combining Zoom’s AI capabilities with ServiceNow’s automation and CRM intelligence enables organizations to scale support without sacrificing personalization. Zoom Virtual Agent can handle customer issues with context-aware responses. Agents benefit from AI Expert Assist to provide real-time sentiment analysis, smart note-taking, and automatic call dispositioning, keeping them focused on high-value interactions instead of repetitive tasks.

    Additionally, Zoom’s AI-first quality management can automatically score every interaction and generate coaching opportunities to drive continuous optimization.

  • Accelerate Resolution Through Seamless Collaboration
    Support doesn’t always end with the first agent. Sometimes it takes a team, from billing to field service to engineering. With Zoom’s collaboration tools accessible within ServiceNow, agents can bring in the right expert without switching tools or losing context, helping them resolve issues faster and with the right team.

Availability

Unified Engagement from Zoom CX and ServiceNow will be available later this year through the ServiceNow Store.

About Zoom

Zoom’s mission is to provide an AI-first work platform for human connection. Reimagine teamwork with Zoom Workplace — Zoom’s open collaboration platform with AI Companion empowers teams to be more productive. Together with Zoom Workplace, Zoom’s Business Services for sales, marketing, and customer experience teams, including Zoom Contact Center, strengthen customer relationships throughout the customer lifecycle. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more information at zoom.com.

About ServiceNow 
ServiceNow (NYSE: NOW) is putting AI to work for people. We move with the pace of innovation to help customers transform organizations across every industry while upholding a trustworthy, human centered approach to deploying our products and services at scale. Our AI platform for business transformation connects people, processes, data, and devices to increase productivity and maximize business outcomes. For more information, visit: www.servicenow.com.

© 2025 ServiceNow, Inc. All rights reserved. ServiceNow, the ServiceNow logo, Now, and other ServiceNow marks are trademarks and/or registered trademarks of ServiceNow, Inc. in the United States and/or other countries. Other company names, product names, and logos may be trademarks of the respective companies with which they are associated.

Zoom Public Relations
Karen Modlin
[email protected]

GlobeNewswire Distribution ID 9445948

Dr. Falk Pharma announces positive results from its pivotal phase 3 trial on norucholic acid in primary sclerosing cholangitis

Freiburg, May 7th, 2025

Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary sclerosing cholangitis. The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam.

Dr. Falk Pharma, a research-based pharmaceutical company specializing in digestive and metabolic medicine, today announced positive results from its pivotal, phase 3 trial (NUC-5) on norucholic acid (NCA) in primary sclerosing cholangitis (PSC).

NUC-5 (NCT03872921) is a double-blind, placebo-controlled trial enrolling 301 patients with PSC, who receive either 1,500 mg NCA or placebo for a total of 192 weeks. At the primary data analysis after 96 weeks of treatment, the primary endpoint of combined partial normalization of blood levels of a liver enzyme linked to PSC (alkaline phosphatase) and no worsening of disease stage on histology was achieved by a statistically significantly greater proportion of patients receiving NCA than placebo. Significant superiority of NCA was also observed in multiple secondary endpoints. The safety results revealed similar rates of study patients with adverse events and serious adverse events between the NCA and placebo groups.

The topline results from NUC-5 will be presented during the Late Breaker session on Saturday, May 10, 2025 at the EASL Congress in Amsterdam.

PSC is a rare, progressive disease in which the immune system attacks the bile ducts in the liver, which leads to fibrosis, or the formation of scar tissue. A considerable proportion of patients develop bile duct, liver, or colorectal cancer, while many others eventually progress to cirrhosis of the liver. No approved pharmaceutical treatment is currently available, and the most effective treatment option is liver transplantation.

“Finding a medicine that effectively treats PSC has been a challenge in the field of hepatology for decades” said Prof. Michael Trauner, Head of the Division of Gastroenterology and Hepatology at the Medical University of Vienna, Austria and principal investigator of the trial. “After so many disappointments in this space, the first positive results from a phase 3 study on PSC is a watershed moment for people with PSC, their families, physicians and the entire PSC community. The results of this study will not only advance patient care but will also give researchers new insights into the disease itself”.

“We are very excited about the positive results of the NUC-5 trial, which was the largest clinical trial on PSC to date which compared biopsies from patients before and after treatment” said Dr. Kai Pinkernell, Managing Director Science and Innovation for Dr. Falk Pharma. “A trial of this duration and involvement is a major undertaking, and we thank all of the participating patients, investigators, and trial staff for their dedication to this trial”.

About norucholic acid

Norucholic acid is an engineered bile acid derivative. Unlike endogenous bile acids, it undergoes no meaningful amidation with glycine or taurine, allowing NCA to be absorbed from bile by cholangiocytes and subsequently re-secreted into bile by hepatocytes in a process called cholehepatic shunting. This together with putative direct anti-inflammatory and anti-fibrotic mechanisms are thought to confer protective effects in PSC. In a previous phase 2 trial, 12 weeks of treatment with NCA was shown to significantly reduce levels of alkaline phosphatase (ALP).

About NUC-5

NUC-5 is a randomized, double-blind, placebo-controlled trial enrolling 301 patients with biopsy-confirmed PSC and levels of ALP at least 1.5-fold greater than the upper limit of normal (ULN). The combined primary endpoint was partial normalization of ALP to <1.5-fold ULN and no worsening of disease stage by histology (Ludwig classification). The key secondary endpoint was partial normalization of ALP to <1.5-fold ULN and no worsening of disease stage by histology (modified Nakanuma staging).

At week 96, 15.1% of patients receiving NCA achieved the primary endpoint compared to 4.2% of placebo patients (p = 0.0048). Similarly, 15.1% of NCA patients versus 5.1% of placebo patients achieved the key secondary endpoint (p = 0.0086). NCA treatment led to improvement by at least 1 Ludwig stage for 25.2% of NCA patients compared to 10.5% of placebo patients (p = 0.0217). Furthermore, worsening by at least one Ludwig stage was observed in 40.4% of placebo patients compared to 20.3% of NCA patients (p = 0.0069). Blood levels of multiple liver enzymes improved under NCA but not placebo. NCA was well tolerated, with similar rates of serious adverse events between the two arms.

NUC-5 is still ongoing, with patients receiving continuous double-blind treatment with either NCA or placebo for an additional 96 weeks. Additional results will be reported after the conclusion of all 192 weeks of double-blind treatment. Patients completing all 192 weeks of double-blind treatment will have the option of receiving open-label treatment with NCA for up to 72 weeks.

Read the abstract here (LBO-001)

About Dr. Falk Pharma GmbH

Dr. Falk Pharma GmbH has been developing and marketing innovative medicines to treat a wide range of gastrointestinal disorders like inflammatory bowel disease or eosinophilic esophagitis as well as hepatobiliary disorders such as primary biliary cholangitis for over 60 years. As the international experts in digestive and metabolic medicine, the company brings together physicians, scientists, and patients to devise new and powerful approaches to patient care. Dr. Falk Pharma engages in pre-clinical and clinical stage research that aims to meaningfully improve therapeutic practice as well as patient health and well-being. A family-owned business with a global presence, Dr. Falk Pharma has ten affiliates in Europe and Australia and is continuously growing. The company has its headquarters and R&D facilities in Freiburg, Germany, its pharmaceutical products are manufactured in Europe, mainly at sites in Germany, France, Italy and Switzerland. Dr. Falk Pharma GmbH employs approximately 1400 individuals globally and 340 in Freiburg.

Further information on Dr. Falk Pharma can be found online: https://drfalkpharma.com


GlobeNewswire Distribution ID 1001095027

Dr. Falk Pharma announces positive results from its pivotal phase 3 trial on norucholic acid in primary sclerosing cholangitis

Freiburg, May 7th, 2025

Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary sclerosing cholangitis. The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam.

Dr. Falk Pharma, a research-based pharmaceutical company specializing in digestive and metabolic medicine, today announced positive results from its pivotal, phase 3 trial (NUC-5) on norucholic acid (NCA) in primary sclerosing cholangitis (PSC).

NUC-5 (NCT03872921) is a double-blind, placebo-controlled trial enrolling 301 patients with PSC, who receive either 1,500 mg NCA or placebo for a total of 192 weeks. At the primary data analysis after 96 weeks of treatment, the primary endpoint of combined partial normalization of blood levels of a liver enzyme linked to PSC (alkaline phosphatase) and no worsening of disease stage on histology was achieved by a statistically significantly greater proportion of patients receiving NCA than placebo. Significant superiority of NCA was also observed in multiple secondary endpoints. The safety results revealed similar rates of study patients with adverse events and serious adverse events between the NCA and placebo groups.

The topline results from NUC-5 will be presented during the Late Breaker session on Saturday, May 10, 2025 at the EASL Congress in Amsterdam.

PSC is a rare, progressive disease in which the immune system attacks the bile ducts in the liver, which leads to fibrosis, or the formation of scar tissue. A considerable proportion of patients develop bile duct, liver, or colorectal cancer, while many others eventually progress to cirrhosis of the liver. No approved pharmaceutical treatment is currently available, and the most effective treatment option is liver transplantation.

“Finding a medicine that effectively treats PSC has been a challenge in the field of hepatology for decades” said Prof. Michael Trauner, Head of the Division of Gastroenterology and Hepatology at the Medical University of Vienna, Austria and principal investigator of the trial. “After so many disappointments in this space, the first positive results from a phase 3 study on PSC is a watershed moment for people with PSC, their families, physicians and the entire PSC community. The results of this study will not only advance patient care but will also give researchers new insights into the disease itself”.

“We are very excited about the positive results of the NUC-5 trial, which was the largest clinical trial on PSC to date which compared biopsies from patients before and after treatment” said Dr. Kai Pinkernell, Managing Director Science and Innovation for Dr. Falk Pharma. “A trial of this duration and involvement is a major undertaking, and we thank all of the participating patients, investigators, and trial staff for their dedication to this trial”.

About norucholic acid

Norucholic acid is an engineered bile acid derivative. Unlike endogenous bile acids, it undergoes no meaningful amidation with glycine or taurine, allowing NCA to be absorbed from bile by cholangiocytes and subsequently re-secreted into bile by hepatocytes in a process called cholehepatic shunting. This together with putative direct anti-inflammatory and anti-fibrotic mechanisms are thought to confer protective effects in PSC. In a previous phase 2 trial, 12 weeks of treatment with NCA was shown to significantly reduce levels of alkaline phosphatase (ALP).

About NUC-5

NUC-5 is a randomized, double-blind, placebo-controlled trial enrolling 301 patients with biopsy-confirmed PSC and levels of ALP at least 1.5-fold greater than the upper limit of normal (ULN). The combined primary endpoint was partial normalization of ALP to <1.5-fold ULN and no worsening of disease stage by histology (Ludwig classification). The key secondary endpoint was partial normalization of ALP to <1.5-fold ULN and no worsening of disease stage by histology (modified Nakanuma staging).

At week 96, 15.1% of patients receiving NCA achieved the primary endpoint compared to 4.2% of placebo patients (p = 0.0048). Similarly, 15.1% of NCA patients versus 5.1% of placebo patients achieved the key secondary endpoint (p = 0.0086). NCA treatment led to improvement by at least 1 Ludwig stage for 25.2% of NCA patients compared to 10.5% of placebo patients (p = 0.0217). Furthermore, worsening by at least one Ludwig stage was observed in 40.4% of placebo patients compared to 20.3% of NCA patients (p = 0.0069). Blood levels of multiple liver enzymes improved under NCA but not placebo. NCA was well tolerated, with similar rates of serious adverse events between the two arms.

NUC-5 is still ongoing, with patients receiving continuous double-blind treatment with either NCA or placebo for an additional 96 weeks. Additional results will be reported after the conclusion of all 192 weeks of double-blind treatment. Patients completing all 192 weeks of double-blind treatment will have the option of receiving open-label treatment with NCA for up to 72 weeks.

Read the abstract here (LBO-001)

About Dr. Falk Pharma GmbH

Dr. Falk Pharma GmbH has been developing and marketing innovative medicines to treat a wide range of gastrointestinal disorders like inflammatory bowel disease or eosinophilic esophagitis as well as hepatobiliary disorders such as primary biliary cholangitis for over 60 years. As the international experts in digestive and metabolic medicine, the company brings together physicians, scientists, and patients to devise new and powerful approaches to patient care. Dr. Falk Pharma engages in pre-clinical and clinical stage research that aims to meaningfully improve therapeutic practice as well as patient health and well-being. A family-owned business with a global presence, Dr. Falk Pharma has ten affiliates in Europe and Australia and is continuously growing. The company has its headquarters and R&D facilities in Freiburg, Germany, its pharmaceutical products are manufactured in Europe, mainly at sites in Germany, France, Italy and Switzerland. Dr. Falk Pharma GmbH employs approximately 1400 individuals globally and 340 in Freiburg.

Further information on Dr. Falk Pharma can be found online: https://drfalkpharma.com


GlobeNewswire Distribution ID 1001095027